Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated
(2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K. M., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034
Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.